Statement: in the primary clinical trial, the curcumin c3 complex group shows a noticeably higher severity of dermatitis in radiation treatment site than the group given a placebo.
Primary_evidence: Outcome Measurement:    Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients   The severity of radiation dermatitis was measured using the Radiation Dermatitis Severity (RDS)Scale which ranges from 0.0 to 4.0 with increments of 0.5. The RDS scale is a revised form of the NIH Common Toxicity Criteria to account for color and subtle texture changes in the skin. The worst dermatitis (i.e., highest RDS score) at the end of treatment was used for the primary analysis of severity of radiation dermatitis in each treatment group. Additionally, we performed repeated measure analyses to examine the severity of dermatitis over time in each arm.   Time frame: 4-7 weeks (prescribed course of radiation) Results 1:    Arm/Group Title: Curcumin C3 Complex   Arm/Group Description: Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks).   Overall Number of Participants Analyzed: 14   Mean (Standard Deviation)   Unit of Measure: units on a scale  2.6         (0.994) Results 2:    Arm/Group Title: Placebo   Arm/Group Description: Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT)(~4-7 weeks).   Overall Number of Participants Analyzed: 16   Mean (Standard Deviation)   Unit of Measure: units on a scale  3.4         (0.554)